Nanosecond Pulsed Electric Fields Enhance the Anti-tumour Effects of the mTOR Inhibitor Everolimus against Melanoma. 2017

Jie Dai, and Shan Wu, and Yan Kong, and Zhihong Chi, and Lu Si, and Xinan Sheng, and Chuanliang Cui, and Jing Fang, and Jue Zhang, and Jun Guo
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital &Institute, Beijing, China.

The PI3K/mTOR/AKT pathway is activated in most melanomas, but mTOR inhibitors used singly have limited activity against advanced melanomas. The application of nanosecond pulsed electric fields (nsPEFs) is a promising cancer therapy approach. In this study, we evaluated the synergistic anti-tumour efficacy of the mTOR inhibitor everolimus in conjunction with nsPEFs against melanoma. The combined treatment of nsPEFs and everolimus gradually decreased cell growth concurrent with nsPEF intensity. nsPEFs alone or combined with everolimus could promote melanoma cell apoptosis, accompanied with a loss in cellular mitochondrial membrane potential and an increase in Ca2+ levels. In vivo experiments showed that a combination of the mTOR inhibitor everolimus and nsPEFs improved the inhibitory effect, and all skin lesions caused by nsPEFs healed in 1 week without any observed adverse effect. Combination treatment induced caspase-dependent apoptosis through the upregulation of the pro-apoptotic factor Bax and downregulation of the anti-apoptotic factor Bcl-2. Everolimus and nsPEFs synergistically inhibited angiogenesis by decreasing the expression of vascular endothelial growth factor (VEGF), VEGF receptor (VEGFR), and CD34. Our findings indicate that nsPEFs in combination with an mTOR inhibitor can be used as a potential treatment approach for advanced melanoma.

UI MeSH Term Description Entries
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D008546 Melanoma, Experimental Experimentally induced tumor that produces MELANIN in animals to provide a model for studying human MELANOMA. B16 Melanoma,Melanoma, B16,Melanoma, Cloudman S91,Melanoma, Harding-Passey,Experimental Melanoma,Experimental Melanomas,Harding Passey Melanoma,Melanomas, Experimental,B16 Melanomas,Cloudman S91 Melanoma,Harding-Passey Melanoma,Melanoma, Harding Passey,Melanomas, B16,S91 Melanoma, Cloudman
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D009389 Neovascularization, Pathologic A pathologic process consisting of the proliferation of blood vessels in abnormal tissues or in abnormal positions. Angiogenesis, Pathologic,Angiogenesis, Pathological,Neovascularization, Pathological,Pathologic Angiogenesis,Pathologic Neovascularization,Pathological Angiogenesis,Pathological Neovascularization
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D004599 Electric Stimulation Therapy Application of electric current in treatment without the generation of perceptible heat. It includes electric stimulation of nerves or muscles, passage of current into the body, or use of interrupted current of low intensity to raise the detection threshold of the skin to pain. Electrotherapy,Electrical Stimulation Therapy,Interferential Current Electrotherapy,Therapeutic Electric Stimulation,Therapeutic Electrical Stimulation,Therapy, Electric Stimulation,Electric Stimulation, Therapeutic,Electrical Stimulation, Therapeutic,Electrotherapy, Interferential Current,Stimulation Therapy, Electric,Stimulation Therapy, Electrical,Stimulation, Therapeutic Electric,Stimulation, Therapeutic Electrical,Therapy, Electrical Stimulation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068338 Everolimus A derivative of sirolimus and an inhibitor of TOR SERINE-THREONINE KINASES. It is used to prevent GRAFT REJECTION in heart and kidney transplant patients by blocking cell proliferation signals. It is also an ANTINEOPLASTIC AGENT. Zortress,40-O-(2-hydroxyethyl)-rapamycin,Afinitor,Certican,RAD 001,RAD001,SDZ RAD,SDZ-RAD,001, RAD,RAD, SDZ
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Jie Dai, and Shan Wu, and Yan Kong, and Zhihong Chi, and Lu Si, and Xinan Sheng, and Chuanliang Cui, and Jing Fang, and Jue Zhang, and Jun Guo
June 2015, Bioelectrochemistry (Amsterdam, Netherlands),
Jie Dai, and Shan Wu, and Yan Kong, and Zhihong Chi, and Lu Si, and Xinan Sheng, and Chuanliang Cui, and Jing Fang, and Jue Zhang, and Jun Guo
December 2013, Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi,
Jie Dai, and Shan Wu, and Yan Kong, and Zhihong Chi, and Lu Si, and Xinan Sheng, and Chuanliang Cui, and Jing Fang, and Jue Zhang, and Jun Guo
April 2012, Hepatobiliary & pancreatic diseases international : HBPD INT,
Jie Dai, and Shan Wu, and Yan Kong, and Zhihong Chi, and Lu Si, and Xinan Sheng, and Chuanliang Cui, and Jing Fang, and Jue Zhang, and Jun Guo
February 2023, Bioelectrochemistry (Amsterdam, Netherlands),
Jie Dai, and Shan Wu, and Yan Kong, and Zhihong Chi, and Lu Si, and Xinan Sheng, and Chuanliang Cui, and Jing Fang, and Jue Zhang, and Jun Guo
August 2010, Pigment cell & melanoma research,
Jie Dai, and Shan Wu, and Yan Kong, and Zhihong Chi, and Lu Si, and Xinan Sheng, and Chuanliang Cui, and Jing Fang, and Jue Zhang, and Jun Guo
April 2016, Oncotarget,
Jie Dai, and Shan Wu, and Yan Kong, and Zhihong Chi, and Lu Si, and Xinan Sheng, and Chuanliang Cui, and Jing Fang, and Jue Zhang, and Jun Guo
December 2003, DNA and cell biology,
Jie Dai, and Shan Wu, and Yan Kong, and Zhihong Chi, and Lu Si, and Xinan Sheng, and Chuanliang Cui, and Jing Fang, and Jue Zhang, and Jun Guo
January 2014, Molecular therapy. Methods & clinical development,
Jie Dai, and Shan Wu, and Yan Kong, and Zhihong Chi, and Lu Si, and Xinan Sheng, and Chuanliang Cui, and Jing Fang, and Jue Zhang, and Jun Guo
July 2023, Microscopy and microanalysis : the official journal of Microscopy Society of America, Microbeam Analysis Society, Microscopical Society of Canada,
Jie Dai, and Shan Wu, and Yan Kong, and Zhihong Chi, and Lu Si, and Xinan Sheng, and Chuanliang Cui, and Jing Fang, and Jue Zhang, and Jun Guo
July 2020, Advanced biosystems,
Copied contents to your clipboard!